Navigation Links
Gen-Probe to Webcast Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference
Date:11/13/2008

SAN DIEGO, Nov. 13 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Lazard Capital Markets 5th Annual Healthcare Conference on Tuesday, November 18, 2008 at approximately 3:10 p.m. Eastern Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investors section of Gen-Probe's website at http://www.gen-probe.com. The webcast will be available for 30 days following the event.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the period ended September 30, 2008, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Paula Izidoro

Investor Relations

858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
2. Gen-Probe to Webcast Presentation at the Bank of America 38th Annual Investment Conference
3. Gen-Probe to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
4. Gen-Probe to Webcast Presentation at the Thomas Weisel Partners Healthcare Conference 2008
5. Gen-Probe Announces Webcast of Second Quarter 2008 Earnings Conference Call
6. 3M Discontinues Collaboration with Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
7. Gen-Probe to Webcast Presentation at the William Blair & Company 28th Annual Growth Stock Conference
8. Gen-Probe to Webcast Presentation at Seventh Annual Needham Biotechnology and Medical Technology Conference
9. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
10. Gen-Probe Launches Cash Tender Offer to Acquire Belgian Molecular Diagnostics Company Innogenetics
11. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/22/2016)... BETHESDA, Md. , June 22, 2016  The American ... by Trade Show Executive Magazine as one of ... Summit on May 25-27 at the Bellagio in ... based on the highest percentage of growth in each of ... number of exhibiting companies and number of attendees. The 2015 ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
Breaking Biology News(10 mins):